GAMMA-ORYZANOL HAS AN EQUIVALENT EFFICACY AS A LIPID-LOWERING AGENT COMPARED TO FIBRATE AND STATIN IN TWO DYSLIPIDEMIA MICE MODELS
Keywords:
Dyslipidemia, Gamma-oryzanol, Statin, Fibrate, Cholesterol, Triglycerides, Glucose, Lipid-loweringAbstract
Objective: A substantial fraction of the population is intolerant or does not respond well to the recommended treatments for dyslipidemia. The purpose of this study was to evaluate the efficacy ofgamma-oryzanol (γ-ORZ) treatment in acute and long-term mouse experimental models of dyslipidemia in comparison toGemfibrozil and Simvastatin.
Methods: For the acute dyslipidemia-induced model, dyslipidemia was induced in 40 mice using a single intra-peritoneal administration of Triton WR-1339. For the long-termmodel, dyslipidemia was induced in 24 mice using a hypercholesterolemic diet over 14 days. Thereafter, animals were divided into different groups of treatment,and orally received treatments with gamma-oryzanol (5, 25, 50mg. kg-1), gemfibrozil or simvastatin. For biochemical analysis, glucose, total cholesterol and triacylglycerols were measured. Body weight and net food intake was registered weekly, and urea, creatinine, AST and ALT levels were evaluated. The data were analyzed by analysis of variance (ANOVA), followed by the Student-Newman-Keuls method,and p value of less than 0.05 was considered significant.
Results: Only the highest dose of γ-ORZ exhibited significant protective effects. Gamma-oryzanol andGemfibrozil treatments reduced total cholesterol and triacylglycerols levels in a similar manner in the acute model. In the second model, γ-ORZ and simvastatin treatments reduced glucose and total cholesterol levels in the same way. In addition, the administration ofγ-ORZ did not cause any adverse events, or significantly altered hepatic enzymes levels, plasmatic urea or creatinine concentrations.
Conclusion: The results of this study suggest that gamma-oryzanol acts as a potential lipid-lowering agent, reducing triglycerides and total cholesterol in dyslipidemia-induced models.
Downloads
References
Gotto AM Jr, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 2012;110(1 Suppl):3A-14A.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52.
World Health Organization. World Health Statistics 2014. Geneva: WHO Press; 2014 [cited 2014];Available from: http://apps.who.int/iris/bitstream/10665/112738/1/9789240692671_eng. pdf?ua=1.
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
Rached FH, Chapman MJ, Kontush A. An overview of the new frontiers in the treatment of atherogenic dyslipidemias. Clin Pharmacol Ther 2014;96(1):57-63.
Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag 2010;6:525-39.
Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 2013;19(17):3124-31.
Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Chiang CW, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atheroscler 2012;224(1):150-3.
Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes 2011;4:155-66.
Ewang-Emukowhate M, Wierzbicki AS. Lipid-lowering agents. J Cardiovasc Pharmacol Ther 2013;18(5):401-11.
De Graaf J, De Sauvage Nolting PR, Van Dam M, Belsey EM, Kastelein JJ, Haydn Pritchard P, et al. Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels. Br J Nutr 2002;88(5):479-88.
Hakala P, Lampi A-M, Ollilainen V, Werner U, Murkovic M, Wähälä K, et al. Steryl phenolic acid esters in cereals and their milling fractions. J Agric Food Chem 2002;50(19):5300-7.
Trautwein EA, Schulz C, Rieckhoff D, Kunath-Rau A, Erbersdobler HF, de Groot WA, et al. Effect of esterified 4-desmethylsterols and-stanols or 4,4′-dimethylsterols on cholesterol and bile acid metabolism in hamsters. Brit J Nutr 2007;87(03):227.
Maud N Vissers, Peter L Zock, Gert W Meijer, Katan MB. Effect of plant sterols from rice bran oil and triterpene alcohols from sheanut oil on serum lipoprotein concentrations in humans. Am J Clin Nutr 2000;72:5.
Rong N, Ausman L, Nicolosi R. Rice bran oil decreases plasma LDL cholesterol by inhibiting dietary-cholesterol absorption. Faseb J 1994;8(4):A162.
Kahlon TS, Chow FI, Sayre RN, Betschart AA. Cholesterol-lowering in hamsters fed rice bran at various levels defatted rice bran and rice bran oil. J Nutr 1992;122:513-9.
Metwally AM, Habib AM, Khafagy SM. Sterols and triterpene alcohols from rice bran oil. Planta Med 1974;25(1):68-72.
Norton RA. Quantitation of steryl ferulate and p-coumarate esters from corn and rice. Lipids 1995;30(3):269-74.
Scavariello EMS, Arellano DB. Gamma-oryzanol: an important component in rice brain oil. Arch Latinoam Nutr 1998;48(1):7-12.
Abe C, Ikeda S, Uchida T, Yamashita K, Ichikawa T. Triton WR1339, an inhibitor of lipoprotein lipase, decreases vitamin e concentration in some tissues of rats by inhibiting its transport to liver. J Nutr 2007;137(2):345-50.
Sikarwar MS, Patil MB. Antihyperlipidemic activity of Salacia chinensis root extracts in triton-induced and atherogenic diet-induced hyperlipidemic rats. Indian J Pharmacol 2012;44(1):88-92.
Wilson TA, Nicolosi RJ, Woolfrey B, Kritchevsky D. Rice bran oil and oryzanol reduce plasma lipid and lipoprotein cholesterol concentrations and aortic cholesterol ester accumulation to a greater extent than ferulic acid in hypercholesterolemic hamsters. J Nutr Biochem 2007;18(2):105-12.
Otway S, Robinson DS. The effect of a non-ionic detergent (Triton WR1339) on the removal of triglyceride fatty acids from the blood of the rat. J Physiol 1967;190:309-19.
Otway S, Robinson DS. The use of a non-ionic detergent (Triton WR1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions. J Physiol 1967;190:321-32.
Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012;18(Suppl 1):1-78.
Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune Neto A, Souza AD, et al. [IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology]. Arq Bras Cardiol 2007;88 Suppl 1:2-19.
Kim SJ, Han D, Moon KD, Rhee JS. Measurement of superoxide dismutaselike activity of natural antioxidants. Biosci Biotechnol Biochem 1995;59:822-6.
Seetharamaiah GS, Chandrasekhara N. Comparative hypocholesterolemic activities of oryzanol, curcumin and ferulic acid in rats. J Food Sei Technol 1993;30:249-52.
Nakayama S, Manabe A, Suzuki J, Sakamoto K, Inagaki T. Comparative effects of two forms of γ-Oryzanol in different sterol compositions on hyperlipidemia induced by cholesterol diet in rats. Japan J Pharmacol 1987;44:135-43.
Son MJ, Rico CW, Nam SH, Kang MY. Effect of oryzanol and ferulic acid on the glucose metabolism of mice fed with a high-fat diet. J Food Sci 2011;76(1):H7-H10.
Makynen K, Chitchumroonchokchai C, Adisakwattana S, Failla M, Ariyapitipun T. Effect of gamma-oryzanol on the bioaccessibility and synthesis of cholesterol. Eur Rev Med Pharmacol Sci 2012;16(1):49-56.